
Edwards Lifesciences Sales Surge 16.7% to $1.6 Billion Driven by Heart Valve Innovation
Edwards Lifesciences CorporationDescription
What this story covers
Edwards Lifesciences reported strong Q1 2026 results, with sales hitting $1.65 billion. Growth was led by a 52% surge in mitral and tricuspid therapies, though the company faces significant ongoing IRS tax disputes and rising manufacturing costs.
Story snapshot
CompanyEdwards Lifesciences Corporation
TickerEW
VariantStandard detailed
Duration12:45
Filing type10-Q
PeriodQ4 2026
IndustryHealthcare & Pharmaceuticals
Accession0001099800-26-000026
Sources1
Full Story Script
Content not available for this story.